Hans T. Schambye, MD PhD


Hans Schambye is a seasoned biotech entrepreneur with extensive experience in drug discovery and development. Previously, Hans served as the Chief Executive Officer of ReceptIcon from 2006 to 2009 and as the CEO of Gastrotech Pharma A/S from 2004 to 2006. Before joining Gastrotech, he was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company. Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Prior to this he had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. Hans holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University.

Anders Pedersen


Anders Pedersen joined Galecto Biotech in 2013 as Chief Operating Officer. Here he is responsible for managing the project portfolio and the collaboration with service providers. Previously, he served as senior vice president of development at CMC Biologics. Anders has more than 25 years of experience in the biopharmaceutical industry. His background experience is in process development and discovery of biopharmaceuticals. Prior to CMC Biologics, he spent 13 years at Novo Nordisk. He was a cofounder of ProFound Pharma, which was later acquired by Maxygen. Anders also served as vice president of project and portfolio management at Life Cycle Pharma and Chief Operating Officer at Recepticon. He has a degree in Chemical Engineering from Danish Technical University in Copenhagen.